Study
| Phase III, randomized, open-label trial (SUNLIGHT) |
| Adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer |
| Trifluridine–tipiracil (FTD–TPI) + Bevacizumab q28 (n=246) vs. Trifluridine–tipiracil (FTD–TPI) (n=246) |
Efficacy
| mOS: 10.8 vs. 7.5 mos, p<0.001 |
| 12-month OS: 43% vs.30% |
| mPFS: 5.6 vs 2.4 mos, p<0.001 |
| 12-month PFS: 16% vs. 1% |
Safety
| Grade≥3 AEs: nNutropenia (43.1% vs. 32.1%), Anemia (6.1% vs. 11.0%), hypertension (5.7% vs 1.2%) |
N Engl J Med 2023; 388:1657-1667
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
http://doi.org/10.1056/NEJMoa2214963
Reviewed by Elvin Chalabiyev, MD on May 20, 2023
